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A bs tr ac t
Background
Gene-expression–profiling studies of primary breast tumors performed by differ-
ent laboratories have resulted in the identification of a number of distinct prognos-
tic profiles, or gene sets, with little overlap in terms of gene identity.
Methods
To compare the predictions derived from these gene sets for individual samples, we 
obtained a single data set of 295 samples and applied five gene-expression–based 
models: intrinsic subtypes, 70-gene profile, wound response, recurrence score, and 
the two-gene ratio (for patients who had been treated with tamoxifen).
Results
We found that most models had high rates of concordance in their outcome predic-
tions for the individual samples. In particular, almost all tumors identified as hav-
ing an intrinsic subtype of basal-like, HER2-positive and estrogen-receptor–nega-
tive, or luminal B (associated with a poor prognosis) were also classified as having 
a poor 70-gene profile, activated wound response, and high recurrence score. The 
70-gene and recurrence-score models, which are beginning to be used in the clini-
cal setting, showed 77 to 81 percent agreement in outcome classification.
Conclusions
Even though different gene sets were used for prognostication in patients with 
breast cancer, four of the five tested showed significant agreement in the outcome 
predictions for individual patients and are probably tracking a common set of bio-
logic phenotypes.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF NC/ACQ SRVCS on February 20, 2018. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
concordance among gene-expression–based predictors for breast cancer
n engl j med 355;6 www.nejm.org august 10, 2006 561
Many studies of gene expression have identified expression profiles and gene sets that are prognostic, predic-
tive, or both for patients with breast cancer.1-12 
Comparisons of the lists of genes derived from 
some of these apparently similar studies show 
that they overlap only slightly, if at all. The rea-
sons for this lower-than-expected overlap are not 
completely known, but they probably include dif-
ferences in the patient cohorts, microarray plat-
forms, and mathematical methods of analysis. An 
important and unanswered question, however, is 
whether these predictors are actually concordant 
with respect to their predictions for individual 
patients. Here, we describe our analysis of a sin-
gle data set on which five prognostic or predictive 
gene-expression–based models were simultane-
ously compared. 
Me thods
Patients
We used a single data set of breast-cancer sam-
ples from 295 women. The gene-expression data 
set was derived by researchers from the Nether-
lands Cancer Institute and Rosetta Inpharmat-
ics–Merck using oligonucleotide microarrays 
(Agilent). Data on relapse-free survival (defined 
as the time to a first event) and overall survival 
were available for all patients.2-4 The clinical in-
formation was obtained from Chang et al.5 Most 
of the patients had stage I or II breast cancer; 165 
had received local therapy alone, 20 had received 
tamoxifen only, 20 had received tamoxifen plus 
chemotherapy, and 90 had received chemother-
apy only.
Statistical Analysis
Gene Sets
We used five prognostic or predictive gene sets 
(and methods) to evaluate the data set. The result-
ing classifications for each patient were recorded 
for each model (Table 1 in the Supplementary Ap-
pendix, available with the full text of this article 
at www.nejm.org). The gene-expression–based 
profiles used were the 70-gene good-versus-poor 
outcome model developed by van de Vijver et al. 
and van’t Veer et al.,2,3 the wound-response model 
developed by Chang et al.,4,5 the recurrence-score 
model developed by Paik et al.,6 the intrinsic-
subtype model (luminal A, luminal B, basal-like, 
HER2-positive and estrogen-receptor–negative 
[HER2+ and ER−], and normal breast-like) de-
veloped by Perou and colleagues,1,9,12,13 and the 
two-gene–ratio model (the ratio of the levels of 
expression of homeobox 13 [HOXB13] and in-
terleukin 17B receptor [IL17BR]).7 (The predic-
tions for each model are presented in the Supple-
mentary Appendix.) The recurrence-score and 
two-gene–ratio models were originally designed 
to predict the outcomes among patients with ER+ 
disease who were receiving tamoxifen.6,7 We there-
fore performed separate analyses for the subgroup 
of ER+ samples and for the complete set of ER+ 
and ER− samples combined. A detailed descrip-
tion of how these methods were applied to the 
295-sample data set is provided in the Supplemen-
tary Appendix.
Survival
To evaluate the prognostic value of each gene-
expression–based model, we performed univari-
ate Kaplan–Meier analysis using the Cox–Mantel 
log-rank test in WinStat for Excel (R. Fitch Soft-
ware). We also used SAS software to perform a 
multivariate Cox proportional-hazards analysis 
of each model individually in a model that included 
estrogen-receptor status (positive vs. negative), 
tumor grade (1 vs. 2 and 1 vs. 3), nodal status (no 
positive nodes vs. one to three positive nodes and 
no positive nodes vs. more than three positive 
nodes), age (as a continuous variable), tumor di-
ameter (2 cm or less vs. more than 2 cm), and 
treatment received (no adjuvant therapy vs. che-
motherapy, hormonal therapy, or both). Relapse-
free survival (defined as the time to a first event) 
and overall survival were the end points. (For 
multivariate analysis of the intrinsic subtypes and 
recurrence score, estrogen-receptor status was 
not included as a variable because it was based 
on the same microarray data that were used in the 
gene-expression models). 
Two-way contingency-table analyses and the 
calculation of Cramer’s V statistic were performed 
with WinStat for Excel. Cramer’s V statistic pro-
vides a quantitative measure of the strength of the 
association between the two variables in a con-
tingency table (information that cannot be ob-
tained from the P value). The values range from 
0 to 1, with 0 indicating no relation and 1 indi-
cating a perfect association. Traditionally, values 
of 0.36 to 0.49 indicate a substantial relation, 
and values of 0.50 or more indicate a strong rela-
tion. The V statistic is a generalization of the more 
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familiar phi statistic for non–two-by-two con-
tingency tables, and for two-by-two tables, the 
V statistic is equal to the phi statistic.14
R esult s
Analysis of All Tumors
For all 295 tumors, all gene-expression–based 
models except the two-gene–ratio model, estro-
gen-receptor status, tumor grade, tumor diame-
ter, and nodal status were significant predictors 
of relapse-free survival and overall survival, ac-
cording to univariate Kaplan–Meier survival analy-
ses (Fig. 1 and Table 1). For the four significant 
models, the groups with a poor outcome were 
as expected: those with a poor 70-gene profile, 
an activated wound response, a high recurrence 
score, and the basal-like, luminal B, and HER2+ 
and ER− intrinsic subtypes.
To evaluate the prognostic value of each gene-
expression–based model, we next performed a 
multivariate Cox proportional-hazards analysis 
— that included estrogen-receptor status, tumor 
grade, nodal status, age, tumor diameter, and 
treatment status — of each model individually 
(Table 2 in the Supplementary Appendix). The 
models based on intrinsic subtype, 70-gene pro-
file, wound response, and recurrence score were 
significant predictors of both relapse-free sur-
vival and overall survival. Thus, each gene-expres-
sion profile (except for the two-gene ratio) added 
new and important prognostic information be-
yond that provided by the standard clinical pre-
dictors. In fact, the 70-gene, recurrence-score and 
intrinsic-subtype profiles were the most predic-
tive variables in each analysis, as ref lected by 
their having the lowest nominal P value.
As a point of reference, we next analyzed each 
model relative to the intrinsic-subtype assign-
ments, which were largely based on an unsuper-
vised analysis of breast-tumor gene-expression 
profiles (Table 2). All 53 basal-like tumors were 
classified as having a high recurrence score and 
a poor 70-gene profile, and 50 were classified as 
having an activated wound-response signature. 
A nearly identical finding was observed for the 
HER2+ and ER− subtype, as well as for the poor-
outcome luminal B subtype that is defined clini-
cally as ER+. Conversely, the normal-like and lu-
minal A tumors showed heterogeneity in terms 
of how they were classified by the other models; 
however, 62 of 70 samples with low recurrence 
scores were of the luminal A subtype. These data 
suggest that if a sample is classified as basal-
like, HER2+ and ER−, or luminal B, then it most 
likely would be in the poor-prognosis groups of 
the 70-gene, wound-response, and recurrence-
score models.
We next compared the results of the 70-gene, 
wound-response, recurrence-score, and two-gene 
models with one another, using two-way contin-
gency-table analyses. For these analyses, we com-
bined the low and intermediate recurrence-score 
categories into a single group, because their sur-
vival curves were not significantly different (Ta-
ble 2E in the Supplementary Appendix). All the 
comparisons yielded significant correlations, with 
the two-gene model having the lowest level of 
correlation. The results of the recurrence score, 
70-gene, and wound-response models were all 
highly correlated (Table 3 in the Supplementary 
Appendix) (P<0.001 by the chi-square test). 
We then assessed the strength of the correla-
tion between the models using Cramer’s V statis-
tic. Comparison of the 70-gene and recurrence-
score models yielded a Cramer’s V statistic of 0.60 
(indicating a strong relation), comparisons of the 
recurrence-score and wound-response models 
yielded a V statistic of 0.42 (indicating a substan-
tial relation), and comparison of the 70-gene and 
wound-response models yielded a V statistic of 
0.36 (indicating a substantial relation). Thus, most 
tumors classified as resulting in a poor outcome 
according to one of these three models were also 
classified as such by the other two. With regard 
to the Cramer’s V values, the model showing the 
best agreement with the other two was the re-
currence score (i.e., of the three, recurrence score 
came the closest to functioning as a consensus 
predictor). To determine whether the use of the 
Figure 1 (facing page).  Kaplan–Meier Survival Estimates 
of Relapse-free Survival and Overall Survival among the 
295 Patients, According to the Intrinsic Subtype (Panels 
A and B), Recurrence Score (Panels C and D), 70-Gene 
Profile (Panels E and F), Wound Response (Panels G and 
H), and Two-Gene Ratio (Panels I and J). 
P values were obtained from the log-rank test. X denotes 
observations that were censored owing to loss to fol-
low-up or on the date of the last contact. 
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three models together would result in a better 
model than the use of any one alone, we derived 
a single model based on the most common find-
ings of the three models. The performance of this 
model according to the Kaplan–Meier analysis 
was similar to that of each of the three models 
but was not noticeably better.
Histologic grade is an important clinical and 
biologic feature of tumors, especially in a com-
parison of the clinical characteristics of grade 1 
and grade 3 breast tumors. An often-asked ques-
tion regarding these gene-expression–based mod-
els is whether the predicted prognosis correlates 
with tumor grade. We therefore performed two-
way contingency-table analyses comparing tumor 
grade and the results of each of four models (70-
gene, wound-response, two-gene ratio, and recur-
rence score [low plus intermediate vs. high]). All 
four models showed significant correlations with 
grade (P<0.001). The 70-gene model was the most 
highly correlated with grade (Cramer’s V statis-
tic, 0.52), followed by recurrence score (V statistic, 
0.48), wound response (V statistic, 0.35), and the 
two-gene ratio (V statistic, 0.25). 
Thus, to varying degrees, all the models cor-
related with grade, but the 70-gene, recurrence-
score, intrinsic-subtype, and wound-response mod-
els added prognostic information beyond that 
provided by the tumor grade. Moreover, the use 
of these four models involved an assay that is 
objective and quantitative and could be automated 
and easily standardized across institutions.
Of the five models, the 70-gene2,3 and recur-
rence-score6,15 models are the most well validated 
and are beginning to be used in the clinical set-
ting to assist in treatment decisions. We there-
fore specifically compared these two models in 
a group of 295 patients with cancer, using a sim-
ple method. We considered low and intermediate 
recurrence scores to be equivalent to a good score 
on the 70-gene model and a high recurrence score 
to be equivalent to a poor score on the 70-gene 
model and then determined how many scores 
agreed between the two models. We observed 
agreement in 239 of 295 samples (81 percent). In 
particular, 81 of the 103 samples with a recur-
rence score of low or intermediate were classified 
as having a good 70-gene profile. 
Table 1. Classification of the Netherlands Cancer Institute Patient Data Set According to Five Gene-Expression–Based 
Models.
Classification 295-Sample Data Set ER+ 225-Sample Data Set
number (percent)
Intrinsic subtype
Luminal A 123 (41.7) 121 (53.8)
Luminal B 55 (18.6) 55 (24.4)
Normal-like 29 (9.8) 24 (10.7)
HER2+ and ER− 35 (11.9) 18 (8.0)
Basal-like 53 (18.0) 7 (3.1)
Recurrence score
Low 70 (23.7) 87 (38.7)
Intermediate 33 (11.2) 18 (8.0)
High 192 (65.1) 120 (53.3)
70-Gene profile
Good 115 (39.0) 113 (50.2)
Poor 180 (61.0) 112 (49.8)
Wound response
Quiescent 67 (22.7) 60 (26.7)
Activated 228 (77.3) 165 (73.3)
Two-gene ratio
Low 137 (46.4) 122 (54.2)
High 158 (53.6) 103 (45.8)
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In this analysis, we compared the capacity of 
each model to predict recurrence in a group of 
patients with either node-negative or node-posi-
tive tumors and with or without adjuvant chemo-
therapy. However, the profiles were developed to 
predict the distant metastasis–free survival among 
patients with node-negative disease only, and they 
are meant to be used either to predict prognosis 
without adjuvant treatment (70-gene predictor) 
or with the use of tamoxifen (recurrence score).
Analysis of Estrogen-Receptor–Positive 
Tumors
Two of the five models (recurrence score and two-
gene ratio) were specifically designed to evaluate 
outcomes in patients with ER+ tumors who were 
treated with tamoxifen. We therefore performed 
the same analyses described above (Table 1) on the 
225 samples in the 295-sample data set that were 
classified as ER+ on the basis of the level of ex-
pression of the estrogen-receptor gene.4 Again, all 
the gene-expression–based models (except for the 
two-gene ratio) were significant predictors of re-
lapse-free survival and overall survival in univar-
iate Kaplan–Meier analyses (Fig. 2). In multivariate 
Cox proportional-hazards analyses (in which each 
model was evaluated individually in a model that 
included the standard clinical variables), the 70-
gene, wound-response, and recurrence-score mod-
els and the luminal A and B intrinsic subtypes 
added considerable prognostic information regard-
ing relapse-free survival and overall survival; each 
gene-expression–based model typically had the 
lowest P value as compared with the traditional 
clinical variables (Table 4 in the Supplementary 
Appendix). The ER+ samples were also classified 
according to intrinsic subtype (Table 3); 7 were 
classified as basal-like and 18 as HER2+ and ER−, 
suggesting that approximately 10 percent of the 
ER+ tumors could be considered ER−, according 
to hierarchical clustering analysis.
As for the 295-sample data set, we performed 
a pairwise comparison of the 70-gene, wound-
response, recurrence-score, and two-gene ratio 
assignments for the 225 ER+ samples, using two-
way contingency-table analyses. All comparisons 
yielded significant correlations except for the 
two-gene model (Table 5 in the Supplementary 
Appendix). The recurrence-score, 70-gene, and 
wound-response profiles were highly correlated 
(P<0.001); the Cramer’s V values were 0.54 for the 
70-gene model as compared with the recurrence-
score model, 0.38 for the recurrence-score mod-
el as compared with the wound-response model, 
Table 2. Classification of Tumor Samples from All 295 Patients, According to the Model Used.
Intrinsic Subtype
No. of 
Patients Recurrence Score 70-Gene Profile Wound Response Two-Gene Ratio
Classification
No. of 
Patients Classification
No. of 
Patients Classification
No. of 
Patients Classification
No. of 
Patients
Basal-like 53 Low 0 Good 0 Quiescent 3 Low 11
Intermediate 0       
High 53 Poor 53 Activated 50 High 42
Luminal A 123 Low 62 Good 87 Quiescent 45 Low 78
Intermediate 25       
High 36 Poor 36 Activated 78 High 45
Luminal B 55 Low 1 Good 9 Quiescent 4 Low 30
Intermediate 4       
High 50 Poor 46 Activated 51 High 25
HER2+ and ER− 35 Low 0 Good 3 Quiescent 0 Low 7
Intermediate 0       
High 35 Poor 32 Activated 35 High 28
Normal-like 29 Low 7 Good 16 Quiescent 15 Low 11
Intermediate 4       
High 18 Poor 13 Activated 14 High 18
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and 0.34 for the 70-gene model as compared with 
the wound-response model. Thus, recurrence score 
showed the best agreement with the other two 
models. We again derived a model based on the 
most common results for the three models, and 
its performance in Kaplan–Meier analysis was 
similar to that of the three individual models.
When the recurrence scores were compared 
with the 70-gene profile scores for the 225-sam-
ple subgroup as they were for the complete data 
set, 173 of the 225 samples (76.9 percent) showed 
agreement. In particular, of the 105 samples with 
low or intermediate recurrence scores, 83 were 
classified as having a good 70-gene profile. 
We did not perform any multivariate Cox pro-
portional-hazards analyses using all predictors 
simultaneously to identify the optimal model for 
either the 225-patient group or the 295-patient 
group. We believed that doing so would not be a 
fair test for any model for which this group was 
a true test set (recurrence score and two-gene ra-
tio) or for those that were developed with the use 
of a different platform (recurrence score, two-
gene ratio, and intrinsic subtype).
Discussion
We analyzed a single data set for which enough 
genes had been assayed to allow the simultane-
ous analysis of five gene-expression–based mod-
els. Four of these models resulted in similar pre-
dictions — for example, each model assigned the 
same samples to the poor-outcome groups. Tu-
mors classified as basal-like, HER2+ and ER−, 
and luminal B by the intrinsic-subtype model 
were almost all classified as having a poor out-
come (regardless of estrogen-receptor status) by 
the 70-gene, recurrence-score, and wound-response 
models. Only within the luminal A and normal-
like intrinsic subtypes was variability in the out-
come predictions found. 
Of the five models analyzed in our study, only 
the two-gene ratio failed to identify significant 
differences in outcome within the data set. In an 
independent data set of patients with ER+ disease 
who were receiving tamoxifen, Reid et al. reported 
that the two-gene model failed to detect differ-
ences in outcome.16 However, Goetz et al. showed 
that in women with node-negative disease from 
the North Central Cancer Treatment Group Study 
89-30-52, the two-gene ratio was a significant 
predictor of relapse-free survival and disease-free 
survival.17 A model based on the analysis of only 
two genes is much more likely to be sensitive to 
technical differences in analysis platforms than 
one based on many genes, and it is possible that 
one of the features representing HOXB13 or 
IL17BR in the Netherlands Cancer Institute data 
set may not faithfully reflect the values seen by 
Ma et al.,7 owing to alternative splicing or differ-
ences in probe-hybridization conditions.
Pairwise comparisons of the 70-gene, wound-
response, recurrence-score, and two-gene mod-
els showed that the results of all but the two-gene 
model were highly concordant. Comparison of 
the 70-gene and recurrence-score models showed 
that their sample predictions agreed in 77 percent 
of patients with ER+ cancer and 81 percent of all 
patients. These analyses suggest that even though 
there was very little gene overlap (the 70-gene 
and recurrence-score profiles overlapped by only 
1 gene: SCUBE2) and different algorithms were 
used, the outcome predictions for the majority of 
patients with breast cancer would be similar. It 
is also likely that the recurrence-score model, 
originally developed for patients with ER+ dis-
ease, is accurate for all patients with breast can-
cer, because almost all (69 of 70) patients with 
ER− tumors were classified as having a high re-
currence score. 
The outcome predictions derived from the 
various models largely overlapped, according to 
multivariate Cox proportional-hazards analyses 
(the 95 percent confidence intervals of the haz-
ard ratios for relapse-free and overall survival are 
given in Table 2 in the Supplementary Appendix). 
The discordance rate of up to 20 percent among 
the patients in different categories led to slight 
differences in outcome prediction and emphasiz-
Figure 2 (facing page). Kaplan–Meier Survival Estimates 
of Relapse-free Survival and Overall Survival among 
the 225 Patients with ER+ Disease, According to the 
Intrinsic Subtype (Panels A and B), Recurrence Score 
(Panels C and D), 70-Gene Profile (Panels E and F), 
Wound Response (Panels G and H), and Two-Gene 
Ratio (Panels I and J). 
P values were obtained from the log-rank test. X de-
notes observations that were censored owing to loss 
to follow-up or on the date of the last contact. 
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es the need for further validation of this ap-
proach. The National Cancer Institute and the 
European Union have designed randomized clin-
ical trials (Trial Assigning Individualized Options 
for Treatment (Rx) [TAILORx] and Translating 
Molecular Knowledge into Early Breast Cancer 
Management Building on the Breast International 
Group network for Improved Treatment Tailor-
ing [TRANSBIG]-Microarray in Node-Negative 
Disease May Avoid Chemotherapy [MINDACT], 
respectively) that will prospectively address the 
prognostic and predictive powers of the recur-
rence-score and 70-gene models, respectively.
Despite the absence of gene overlap, the dif-
ferent gene models yielded similar predictions 
largely because they reflected common cellular 
phenotypes, which encompass the consistent dif-
ferences in ER+ (i.e., luminal) breast cancer and 
ER– (basal-like and HER2+ and ER−) breast can-
cers. Although these differences are correlated 
with histologic grade, it is clear that these pro-
files provided additional information beyond that 
provided by grade. Our findings also show that 
outcomes can readily be predicted by a large num-
ber of genes and that a model that uses a suffi-
ciently representative subgroup of these genes 
should be effective. This is consistent with an ob-
servation made by Son et al., who reported that 
approximately 19,000 genes are differentially ex-
pressed in various tissues and that any randomly 
selected subgroup that is sufficiently large (ap-
proximately 100 genes) reproduces the hierarchi-
cal clustering obtained with the use of the full 
gene set.18 
We conclude that overlap in gene identity 
among gene-expression profiles is not a good 
measure of reproducibility and that the classifi-
cation of individual samples is the relevant mea-
sure of concordance. Our results are encourag-
ing and can be interpreted to mean that although 
different gene sets are being used as predictors, 
they each track a common set of biologic char-
acteristics that are present in different groups of 
patients with breast cancer, resulting in similar 
predictions of outcome.
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Table 3. Classification of Tumor Samples from the 225 Patients with ER+ Disease, According to the Model Used.
Intrinsic Subtype
No. of 
Patients Recurrence Score 70-Gene Profile Wound Response Two-Gene Ratio
Classification
No. of 
Patients Classification
No. of 
Patients Classification
No. of 
Patients Classification
No. of 
Patients
Basal-like 7 Low 1 Good 0 Quiescent 0 Low 1
Intermediate 1       
High 5 Poor 7 Activated 7 High 6
Luminal A 121 Low 68 Good 87 Quiescent 45 Low 77
Intermediate 13       
High 40 Poor 34 Activated 76 High 44
Luminal B 55 Low 2 Good 9 Quiescent 4 Low 30
Intermediate 2       
High 51 Poor 46 Activated 51 High 25
HER2+ and ER− 18 Low 1 Good 2 Quiescent 0 Low 5
Intermediate 0       
High 17 Poor 16 Activated 18 High 13
Normal-like 24 Low 15 Good 15 Quiescent 11 Low 9
Intermediate 2       
High 7 Poor 9 Activated 13 High 15
 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF NC/ACQ SRVCS on February 20, 2018. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
concordance among gene-expression–based predictors for breast cancer
n engl j med 355;6 www.nejm.org august 10, 2006 569
References
Sorlie T, Tibshirani R, Parker J, et al. 
Repeated observation of breast tumor sub-
types in independent gene expression data 
sets. Proc Natl Acad Sci U S A 2003;100:
8418-23.
van de Vijver MJ, He YD, van ’t Veer LJ, 
et al. A gene-expression signature as a pre-
dictor of survival in breast cancer. N Engl 
J Med 2002;347:1999-2009.
van’t Veer LJ, Dai H, van de Vijver MJ, 
et al. Gene expression profiling predicts 
clinical outcome of breast cancer. Nature 
2002;415:530-6.
Chang HY, Nuyten DS, Sneddon JB, et 
al. Robustness, scalability, and integration 
of a wound-response gene expression sig-
nature in predicting breast cancer surviv-
al. Proc Natl Acad Sci U S A 2005;102:3738-
43.
Chang HY, Sneddon JB, Alizadeh AA, 
et al. Gene expression signature of fibro-
blast serum response predicts human can-
cer progression: similarities between tu-
mors and wounds. PLoS Biol 2004;2(2):E7.
Paik S, Shak S, Tang G, et al. A multi-
gene assay to predict recurrence of tamox-
ifen-treated, node-negative breast cancer. 
N Engl J Med 2004;351:2817-26.
1.
2.
3.
4.
5.
6.
Ma XJ, Wang Z, Ryan PD, et al. A two-
gene expression ratio predicts clinical 
outcome in breast cancer patients treat-
ed with tamoxifen. Cancer Cell 2004;5:
607-16.
Bertucci F, Finetti P, Rougemont J, et 
al. Gene expression profiling identifies 
molecular subtypes of inflammatory breast 
cancer. Cancer Res 2005;65:2170-8.
Sorlie T, Perou CM, Tibshirani R, et 
al. Gene expression patterns of breast car-
cinomas distinguish tumor subclasses with 
clinical implications. Proc Natl Acad Sci 
U S A 2001;98:10869-74.
Sotiriou C, Neo SY, McShane LM, et 
al. Breast cancer classification and prog-
nosis based on gene expression profiles 
from a population-based study. Proc Natl 
Acad Sci U S A 2003;100:10393-8.
Wang Y, Klijn JG, Zhang Y, et al. Gene-
expression profiles to predict distant me-
tastasis of lymph-node-negative primary 
breast cancer. Lancet 2005;365:671-9.
Hu Z, Fan C, Oh DS, et al. The molecu-
lar portraits of breast tumors are conserved 
across microarray platforms. BMC Geno-
mics 2006;7:96.
Perou CM, Sorlie T, Eisen MB, et al. 
7.
8.
9.
10.
11.
12.
13.
Molecular portraits of human breast tu-
mours. Nature 2000;406:747-52.
van Belle G, Fisher L. Biostatistics: 
a methodology for the health sciences. 
2nd ed. Hoboken, N.J.: Wiley-Interscience, 
2004.
Paik S, Shak S, Tang G, et al. Gene 
expression and benefit of chemotherapy 
in women with node-negative, estrogen-
receptor–positive breast cancer. J Clin 
Oncol (in press).
Reid JF, Lusa L, De Cecco L, et al. Lim-
its of predictive models using microarray 
data for breast cancer clinical treatment 
outcome. J Natl Cancer Inst 2005;97:927-
30.
Goetz MP, Suman VJ, Ingle JN, et al. 
A two-gene expression ratio of homeobox 
13 and interleukin-17B receptor for pre-
diction of recurrence and survival in wom-
en receiving adjuvant tamoxifen. Clin Can-
cer Res 2006;12:2080-7.
Son CG, Bilke S, Davis S, et al. Data-
base of mRNA gene expression profiles of 
multiple human organs. Genome Res 
2005;15:443-50.
Copyright © 2006 Massachusetts Medical Society.
14.
15.
16.
17.
18.
CLINICAL TRIAL REGISTRATION
The Journal encourages investigators to register their clinical trials 
in a public trials registry. The members of the International Committee 
of Medical Journal Editors plan to consider clinical trials for publication 
only if they have been registered (see N Engl J Med 2004;351:1250-1). 
The National Library of Medicine’s www.clinicaltrials.gov is a free registry, 
open to all investigators, that meets the committee’s requirements.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF NC/ACQ SRVCS on February 20, 2018. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
